Evidence map›Paper›PMID 27600227›Full record

ArticleMicroarrays (Basel, Switzerland)2015

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Clare Coveney, David J Boocock, Robert C Rees, Suha Deen, Graham R Ball

Abstract read
In one paragraph

Article in Microarrays (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Clare CoveneyJohn van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK. clare.coveney@ntu.ac.uk.
David J BoocockJohn van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK. david.boocock@ntu.ac.uk.
Robert C ReesJohn van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK. robert.rees@ntu.ac.uk.
Suha DeenDepartment of Histopathology, Queens Medical Centre, Derby Road, Nottingham, Nottinghamshire NG7 2NH, UK. suha.deen@nuh.nhs.uk.
Graham R BallJohn van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK. graham.ball@ntu.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this applies to the 7000 new cases diagnosed yearly in the UK. Stratification of patients with this heterogeneous disease, based on active molecular pathways, would aid a targeted treatment improving the prognosis for many cases. While hundreds of genes have been associated with ovarian cancer, few have yet been verified by peer research for clinical significance. Here, a meta-analysis approach was applied to two carefully selected gene expression microarray datasets. Artificial neural networks, Cox univariate survival analyses and T-tests identified genes whose expression was consistently and significantly associated with patient survival. The rigor of this experimental design increases confidence in the genes found to be of interest. A list of 56 genes were distilled from a potential 37,000 to be significantly related to survival in both datasets with a FDR of 1.39859 × 10(-11), the identities of which both verify genes already implicated with this disease and provide novel genes and pathways to pursue. Further investigation and validation of these may lead to clinical insights and have potential to predict a patient's response to treatment or be used as a novel target for therapy.

Indexed as

artificial neural networksbiomarkersmeta-analysisovarian cancersurvival analysistranscriptomics

Identifiers

PMID27600227
PMCPMC4996375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.